National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Encorafenib (Braftovi®) in combination with cetuximab. HTA ID: 20037

Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 05/08/2020
Rapid review completed 28/09/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib plus cetuximab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/09/2020
Pre-submission consultation with Applicant 15/03/2021
Full HTA submission received from Applicant 29/06/2021
Preliminary review sent to Applicant 17/09/2021
NCPE assessment re-commenced 05/11/2021
Factual accuracy sent to Applicant 23/12/2021
NCPE assessment re-commenced 10/01/2022
NCPE assessment completed 28/01/2022
NCPE assessment outcome The NCPE recommends that encorafenib, in combination with cetuximab, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.